http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SU-1712873-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_beff47753def4be4827e5cac035df0d0 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate | 1989-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1992-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20baae0331a8168fdc0832d00ad6f1f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa4396d10fa8846ffc5575af5ccf6cb0 |
| publicationDate | 1992-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | SU-1712873-A1 |
| titleOfInvention | Method for determining fibrin monomer polymerization disorders in the patient blood plasma |
| abstract | The invention relates to medicine, in particular to hemostasis, and can be used to study the blood coagulation polymerization phase in the diagnosis of hemorrhagic diathesis, thrombosis. DIC syndromes, systemic vasculitis. The aim of the invention is to improve the accuracy of the method. To do this, in violation of the polymerization of the fibrin monomer, the patient's plasma is used as the liquid leading to polymerization, which is added to the soluble Healthy fibrin monomer and when the polymerization rate is lengthened, a diagnosis of the polymerization inhibitor is diagnosed, and in the absence of lengthening, disfibrinogenemia. |
| priorityDate | 1989-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 19.